Health and Healthcare
Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)
Published:
Last Updated:
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.
The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.
The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
